A multicenter, randomized, double-blind, placebo controlled phase III study of monosialoganglioside (GM1) preventing neurotoxicity induced by cisplatin-based chemotherapy in non-small cell lung cancer patients.

被引：0
|
作者：
Zhang, Li
Zhou, Ting
Ma, Yuxiang
Yang, Yunpeng
Fang, Wenfeng
Zhao, Yuangyuan
Hong, Shaodong
Fang, Chan
Zhang, Jiexia
Zhang, Hongyu
Zhao, Hongyun
Huang, Yan
机构：
[1] Sun Yat Sen Univ, Canc Ctr, Guangzhou, Peoples R China
[2] Collaborat Innovat Ctr Canc Med, Guangzhou, Peoples R China
[3] Hosp Tradit Chinese Med Zhongshan, Zhongshan, Peoples R China
[4] China State Key Lab Resp Dis, Guangzhou, Peoples R China
[5] Guangzhou Inst Resp Dis, Guangzhou, Peoples R China
[6] Guangzhou Med Univ, Affiliated Hosp 1, Guangzhou, Peoples R China
[7] Sun Yat Sen Univ, Affiliated Hosp 5, Zhuhai, Peoples R China
[8] Sun Yat Sen Univ, Caner Ctr, State Key Lab Oncol South China, Guangzhou, Peoples R China
[9] Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.TPS10142
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS10142
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase III, randomized, double-blind, placebo-controlled, multicenter study of lipegfilgrastim in patients with non-small cell lung cancer receiving myelosuppressive therapy
    Volovat, Constantin
    Bondarenko, Igor M.
    Gladkov, Oleg A.
    Elsaesser, Reiner
    Buchner, Anton
    Bias, Peter
    Mueller, Udo
    SPRINGERPLUS, 2015, 4
  • [2] Antiemetic efficacy of casopitant, a novel NK-1 receptor antagonist, in patients with non-small cell lung cancer receiving cisplatin-based chemotherapy: subgroup analysis from a randomized, double-blind, placebo-controlled phase III trial
    Grunberg, Steven M.
    Lane, Stephen R.
    Wissel, Paul S.
    Russo, Mark W.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S368 - S368
  • [3] A phase III, randomized, double-blind, controlled trial of carboxyamidotriazole plus chemotherapy for the treatment of advanced non-small cell lung cancer
    Si, Xiaoyan
    Wang, Jinwan
    Cheng, Ying
    Shi, Jianhua
    Cui, Liying
    Zhang, Helong
    Huang, Yunchao
    Liu, Wei
    Chen, Lei
    Zhu, Jiang
    Zhang, Shucai
    Li, Wei
    Sun, Yan
    Wang, Hanping
    Zhang, Xiaotong
    Wang, Mengzhao
    Yang, Lin
    Zhang, Li
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [4] CISPLATIN-BASED CHEMOTHERAPY IN ELDERLY PATIENTS WITH NON-SMALL CELL LUNG CANCER
    Li, Jian
    Li, Xiao-Qin
    Du, Young-Jie
    Ge, Li-Ping
    Dai, Chun-Hua
    Chen, Ping
    INTERNATIONAL JOURNAL OF GERONTOLOGY, 2010, 4 (01) : 28 - 36
  • [5] A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer - The FALUCA study
    Lu, Shun
    Chen, Gongyan
    Sun, Yuping
    Sun, Sanyuan
    Chang, Jianhua
    Yao, Yu
    Chen, Zhendong
    Ye, Feng
    Lu, Junguo
    Shi, Jianhua
    He, Jianxing
    Liu, Xiaoqing
    Zhang, Yiping
    Liu, Zhihua
    Fang, Jian
    Cheng, Ying
    Hu, Chunhong
    Mao, Weidong
    Hu, Yanping
    Gong, Youling
    Shan, Li
    Yang, Zhixiong
    Song, Yong
    Li, Wei
    Bai, Chong
    Wang, Buhai
    Ma, Rui
    Zheng, Zhendong
    Liu, Mingfang
    Jie, Zhijun
    Cao, Lejie
    Liao, Wangjun
    Pan, Hongming
    Huang, Dongning
    Chen, Yuan
    Yang, Jinji
    Qin, Shukui
    Ma, Shenglin
    Liang, Li
    Liu, Zhe
    Zhou, Jianying
    Tao, Min
    Huang, Yijiang
    Qiu, Feng
    Huang, Yunchao
    Guan, Sha
    Peng, Mengye
    Su, Weiguo
    LUNG CANCER, 2020, 146 : 252 - 262
  • [6] A MULTICENTER PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO CONTROLLED TRIAL OF PRAVASTATIN ADDED TO FIRST-LINE STANDARD CHEMOTHERAPY IN PATIENTS WITH SMALL CELL LUNG CANCER (SCLC)
    Seckl, Michael J.
    Ottensmeier, Christian
    Cullen, Michael
    Schmid, Peter
    James, Lindsay
    Wadsworth, Christina
    Farrant, Hannah
    Muthukumar, Dakshinamoorthy
    Thompson, Joyce
    Harden, Susan
    Middleton, Gary
    Fife, Kate
    Crosse, Barbara
    Taylor, Paul
    Khan, Ifty
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S219 - S219
  • [7] Phase III randomized, placebo-controlled, double-blind study of monosialotetrahexosylganglioside in prevention of oxaliplatin-induced neurotoxicity in stage II/III colorectal cancer patients.
    Li, Yu-hong
    Wang, De-Shen
    Wang, Zhiqiang
    Peng, Jie-wen
    Wang, Wei
    Feng, Fen
    Deng, Yanhong
    Zhang, Jianwei
    Wang, Fenghua
    Ren, Chao
    Wang, Feng
    Jin, Ying
    Xie, Chuanbo
    Tan, Qiong
    Chen, Gong
    Xu, Rui-hua
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [8] Cardiotoxicity of cisplatin-based chemotherapy in advanced non-small cell lung cancer patients
    Demkow, Urszula
    Stelmaszczyk-Emmel, Anna
    RESPIRATORY PHYSIOLOGY & NEUROBIOLOGY, 2013, 187 (01) : 64 - 67
  • [9] Multicenter randomized double-blind controlled phase III study of hhpg-19K as prophylactic therapy in patients with advanced non-small cell lung cancer (NSCLC) receiving myelosuppressive chemotherapy
    Zhou, Caicun
    Huang, Yunchao
    An, Changshan
    Wang, Donglin
    He, Jianxing
    Zhou, Fuxiang
    Chen, Gongyan
    Li, Yali
    Wu, Changping
    Wu, Gang
    Song, Xia
    Gao, Jianfei
    Liu, Wei
    Li, Baolan
    Shi, Jianhua
    Huang, Cheng
    Yu, Ping
    Feng, Jueping
    Liu, Yi
    Xia, Jielai
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [10] Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC)
    Tran, Hai T.
    Zinner, Ralph G.
    Blumenschein, George R., Jr.
    Oh, Yun W.
    Papadimitrakopoulou, Vassiliki A.
    Kim, Edward S.
    Lu, Charles
    Malik, Mubashira
    Lum, Bert L.
    Herbst, Roy S.
    INVESTIGATIONAL NEW DRUGS, 2011, 29 (03) : 499 - 505
12345